NeuroBiomarK: Study of Neurological Damage From Coronavirus Disease (COVID-19)

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Recruiting

CT.gov ID

NCT05079373

Collaborator

(none)

250

Enrollment

Location

Anticipated Duration (Months)

13.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The objective of this study is to support the exploration of the NEURO-COVID-19 database and in particular to carry out the post-treatments necessary to derive quantitative information on the characterization of the lesion load, in particular with regard to of the vascular tree

Condition or Disease	Intervention/Treatment	Phase
COVID-19

Study Design

Study Type:

Observational

Anticipated Enrollment :

250 participants

Observational Model:

Case-Control

Time Perspective:

Retrospective

Official Title:

Study of Neurological Damage From Coronavirus Disease (COVID-19): Extraction of Quantitative Imaging Biomarkers for the Characterization of Pathological Profiles

Actual Study Start Date :

Apr 1, 2021

Anticipated Primary Completion Date :

Oct 9, 2022

Anticipated Study Completion Date :

Oct 31, 2022

Outcome Measures

Primary Outcome Measures

Retrospective study of the neurological damage in patients with Covid-19 [Files analysed retrospectively from January 01, 2020 to October 31, 2021 will be examined]]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion criteria:

Adult patient (≥18 years old)
COVID + patient presenting with neurological symptoms leading to an MRI.
Patient taken care of in one of the care centers associated with this research
Patient not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.